CN104116796B - A kind of pharmaceutical composition for the treatment of cyclomastopathy - Google Patents
A kind of pharmaceutical composition for the treatment of cyclomastopathy Download PDFInfo
- Publication number
- CN104116796B CN104116796B CN201410394695.6A CN201410394695A CN104116796B CN 104116796 B CN104116796 B CN 104116796B CN 201410394695 A CN201410394695 A CN 201410394695A CN 104116796 B CN104116796 B CN 104116796B
- Authority
- CN
- China
- Prior art keywords
- grams
- radix
- treatment
- cyclomastopathy
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of pharmaceutical composition for the treatment of cyclomastopathy, it comprises the medical materials such as Radix Glycyrrhizae, the Radix Paeoniae Alba, the Radix Angelicae Dahuricae, Herba Erigerontis Annui, Ilex purpurea Hassk.[I.chinensis Sims, Folium Eucalypti Robustae, Rhizoma Curculiginis.The pharmaceutical composition for the treatment of cyclomastopathy of the present invention has good effect, and cure rate is high, and cost is low, and medicine source is wide, without any side effects, stable curative effect, not easily the advantage such as recurrence.
Description
Technical field
The present invention relates to Gynecology, relate in particular to a kind of pharmaceutical composition for the treatment of cyclomastopathy.
Background technology
Cyclomastopathy is clinical modal cystic hyperplasia of breast, and its sickness rate accounts for the 30%-50% of the women of child-bearing age, mastopathy 3/4 and morbidity still in rise trend.Domestic and international research shows, cyclomastopathy and breast carcinoma have close relationship, there is breast cancer risk than healthy women height 1.4-1.5 doubly in it, modern medicine thinks that cyclomastopathy is due to endocrine disturbance, caused by estrogen increases or estrogen and progestogen is out of proportion and in mammary gland tissue, estrogen receptor increases.Be multiple disease clinically at present, therefore need constantly to find new effective medicine.
Summary of the invention
The object of this invention is to provide a kind of pharmaceutical composition for the treatment of cyclomastopathy.
In order to realize object of the present invention, the invention provides a kind of pharmaceutical composition for the treatment of cyclomastopathy, it comprises the crude drug of following weight portion: Radix Glycyrrhizae 1-20 part, Radix Paeoniae Alba 10-30 part and Radix Angelicae Dahuricae 1-10 part.
Preferably, the pharmaceutical composition for the treatment of cyclomastopathy of the present invention comprises the crude drug of following weight portion: 10 parts, Radix Glycyrrhizae, the Radix Paeoniae Alba 15 parts and the Radix Angelicae Dahuricae 8 parts.
More preferably, the pharmaceutical composition for the treatment of cyclomastopathy of the present invention also comprises the crude drug of following weight portion: Herba Erigerontis Annui 10-20 part, Ilex purpurea Hassk.[I.chinensis Sims 10-30 part, Folium Eucalypti Robustae 1-20 part, Rhizoma Curculiginis 1-10 part, Herba Ixeritis chinensis 1-5 part, Herba Liparidis nervosae 10-30 part, Radix Pulsatillae 1-20 part, Herba Fimbristylis dichotomae 10-30 part, when medicine 1-10 part, sow grass 1-10 part, tetramerous jasminorange leaf 1-10 part, Semen Myristicae 1-10 part, GUANGXIANG rattan 10-30 part, Radix Polygalae 1-10 part, little Rubus pectinellus 10-30 part and Lindera angustifolia Cheng 10-20 part.
Most preferably, the pharmaceutical composition for the treatment of cyclomastopathy of the present invention also comprises the crude drug of following weight portion: Herba Erigerontis Annui 15 parts, Ilex purpurea Hassk.[I.chinensis Sims 20 parts, Folium Eucalypti Robustae 10 parts, Rhizoma Curculiginis 5 parts, Herba Ixeritis chinensis 3 parts, Herba Liparidis nervosae 15 parts, the Radix Pulsatillae 10 parts, Herba Fimbristylis dichotomae 20 parts, when medicine 9 parts, sow grass 8 parts, tetramerous jasminorange leaf 6 parts, Semen Myristicae 5 parts, 15 parts, GUANGXIANG rattan, Radix Polygalae 6 parts, little Rubus pectinellus 20 parts and Lindera angustifolia Cheng 12 parts.
Preferably, described pharmaceutical composition can be tablet, dispersible tablet, disintegrating tablet, rapidly dissolving tablet, enteric coatel tablets, ointment or decoction.
Generally acknowledged that " organic conception ", " determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs ", " compound recipe use ", " compound compatibility medication is as used military forces " are the traditional Chinese medical science the most effective most scientific several large advantages at present, wherein " compound compatibility medication is as used military forces " is the original theory of Chinese medicine of very science.The tight compatibility that in traditional Chinese medical science prescription, each medicine is all linked with one another as arrayed troops for battle is that it is better than the effective means of Western medicine formula.Tcm prescription theory is thought, each prescription, not only need to select the appropriate compatibility of suitable medicament according to etiology and pathogenesis, also should meet the basic structure of prescription simultaneously, the i.e. prescription compatibility theory of " monarch, minister, help, make ", the prescription compatibility of so-called " monarch, minister, help, make " is exactly that it is based upon the scientific matching on the comprehensive judgement basis of disease pathogenesis.In medical side by too many levels, Mutiple Targets Integrate adjustment biological mechanism, can to obtain than Western medicine more lastingly, the more therapeutic effect that has no side effect of green natural, and this curative effect be based upon the above-mentioned traditional Chinese medical science tradition original theory accurate instruction on, the present invention just have followed this principle.
For compositions of the present invention, according to the prescription compatibility theory of " monarch, minister, help, make ", Herba Fimbristylis dichotomae and little Rubus pectinellus are monarch drug; Herba Erigerontis Annui, the Radix Paeoniae Alba, Ilex purpurea Hassk.[I.chinensis Sims, Herba Liparidis nervosae, the Radix Pulsatillae, GUANGXIANG rattan are ministerial drug; The Radix Angelicae Dahuricae, Folium Eucalypti Robustae, Rhizoma Curculiginis, Herba Ixeritis chinensis, when medicine, sow grass, tetramerous jasminorange leaf, Semen Myristicae, Radix Polygalae, Lindera angustifolia Cheng be adjuvant drug; Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription, for making medicine.The pharmaceutical composition for the treatment of cyclomastopathy of the present invention has good effect, and cure rate is high, and cost is low, and medicine source is wide, without any side effects, stable curative effect, not easily the advantage such as recurrence.
Detailed description of the invention
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Unless otherwise stated, the percent in the present invention is percetage by weight.
Embodiment ointment of the present invention
Take 10 grams, Radix Glycyrrhizae, the Radix Paeoniae Alba 15 grams, the Radix Angelicae Dahuricae 8 grams, Herba Erigerontis Annui 15 grams, Ilex purpurea Hassk.[I.chinensis Sims 20 grams, Folium Eucalypti Robustae 10 grams, Rhizoma Curculiginis 5 grams, Herba Ixeritis chinensis 3 grams, Herba Liparidis nervosae 15 grams, the Radix Pulsatillae 10 grams, Herba Fimbristylis dichotomae 20 grams, when medicine 9 grams, sow grass 8 grams, tetramerous jasminorange leaf 6 grams, Semen Myristicae 5 grams, 15 grams, GUANGXIANG rattan, Radix Polygalae 6 grams, little Rubus pectinellus 20 grams and Lindera angustifolia Cheng 12 grams, pulverize, cross 100 mesh sieves, add 200 grams of lanolines, stir, obtain ointment of the present invention.
Experimental example
Physical data
Be collected in year March in March, 2013 to 2014 routine to the female patient 30 that my institute is medical, minimum 18 years old of age, maximum 65 years old, average 36 years old; The course of disease is the shortest 30 days, the longest 1 year, one-sided ill 15 examples of breast, ill 15 examples of bilateral.
Inclusion criteria
(1) meet Shanghai Health Bureau in 2003 compile " Shanghai City Chinese medical disease conventional treatment " (Shanghai Health Bureau. Shanghai City Chinese medical disease conventional treatment [M] .2 version. Shanghai: publishing house of Shanghai Univ. of Traditional Chinese Medicine, the diagnosis basis of nodules of the breast 2003:159), and through the inspection of mammary gland Color B-Type Ultrasonic be diagnosed as cyclomastopathy and except other pathological changes.(2) associated medication therapies has been stopped using to reach more than 2 weeks before this time treatment.(3) development of breast that except, other reasons causes abnormal (as trimester of pregnancy, age of sucking, medicine cause, pituitary tumor).
The ointment prepared in embodiment is used to treat, every day twice, evenly coating 30 grams on each ill breast at every turn, continuously treatment 10 days.
Observation index
(1) observe estrogen 6: all carry out blood test before and after all cases treatment and measure 6 hormonal readinesses such as serum glycol luteal phase (E2), progesterone (P), testosterone (T), follicule-stimulating hormone (FSH) (FSH), lutropin (LH), lactotropin (PRL), understand gonadal hormone situation of change before and after treatment.(2) clinical observation: Clinical symptom and sign situation of change before and after main detection treatment, is mainly mastalgia, lump in breast situation of change.
Criterion of therapeutical effect
Efficacy assessment standard
By Shanghai Health Bureau in 2003 compile " Shanghai City Chinese medical disease conventional treatment " (Shanghai Health Bureau. Shanghai City Chinese medical disease conventional treatment [M] .2 version. Shanghai: publishing house of Shanghai Univ. of Traditional Chinese Medicine, 2003:159) formulate criterion of therapeutical effect:
Cure: mastalgia and lump disappear; Take a turn for the better: lump in breast reduces, pain obviously alleviates and even disappears; Invalid: lump in breast and pain even increase the weight of without improvement.
Result
Through treatment, find in 30 routine patients, cure 26 examples, take a turn for the better 4 examples.
Before and after treatment, clinical symptoms and sign improvement see the following form
After visible treatment, patient's symptom and sign all obviously improves (P<0.01).
Before and after treatment, the change of serum indices is compared and is seen the following form luteal phase
Note: compare with before treatment, * P < 005.
Claims (1)
1. treat the ointment of cyclomastopathy for one kind, it is characterized in that, it is made up by following method of following bulk drugs: take 10 grams, Radix Glycyrrhizae, the Radix Paeoniae Alba 15 grams, the Radix Angelicae Dahuricae 8 grams, Herba Erigerontis Annui 15 grams, Ilex purpurea Hassk.[I.chinensis Sims 20 grams, Folium Eucalypti Robustae 10 grams, Rhizoma Curculiginis 5 grams, Herba Ixeritis chinensis 3 grams, Herba Liparidis nervosae 15 grams, the Radix Pulsatillae 10 grams, Herba Fimbristylis dichotomae 20 grams, when medicine 9 grams, sow grass 8 grams, tetramerous jasminorange leaf 6 grams, Semen Myristicae 5 grams, 15 grams, GUANGXIANG rattan, Radix Polygalae 6 grams, little Rubus pectinellus 20 grams and Lindera angustifolia Cheng 12 grams, pulverize, cross 100 mesh sieves, add 200 grams of lanolines, stir, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410394695.6A CN104116796B (en) | 2014-08-12 | 2014-08-12 | A kind of pharmaceutical composition for the treatment of cyclomastopathy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410394695.6A CN104116796B (en) | 2014-08-12 | 2014-08-12 | A kind of pharmaceutical composition for the treatment of cyclomastopathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104116796A CN104116796A (en) | 2014-10-29 |
| CN104116796B true CN104116796B (en) | 2016-03-09 |
Family
ID=51762576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410394695.6A Expired - Fee Related CN104116796B (en) | 2014-08-12 | 2014-08-12 | A kind of pharmaceutical composition for the treatment of cyclomastopathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104116796B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105559061A (en) * | 2015-12-19 | 2016-05-11 | 韦盛盟 | Instant powder for treating breast nodules and preparation method thereof |
| CN105558691A (en) * | 2015-12-19 | 2016-05-11 | 韦盛盟 | Drink for preventing and treating breast nodules and preparation method thereof |
| CN111700962A (en) * | 2020-08-09 | 2020-09-25 | 仲崇允 | External traditional Chinese medicine preparation for treating mastitis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1569187A (en) * | 2004-04-27 | 2005-01-26 | 秦学彬 | Pure Chinese medicine for treating infecundity, dysgenesia and mastopathia |
| CN101564521A (en) * | 2009-05-20 | 2009-10-28 | 石振刚 | External plaster for treating hyperplasia of mammary glands |
| CN102091296A (en) * | 2011-01-24 | 2011-06-15 | 郭智义 | Medicament for treating breast hyperplasia |
-
2014
- 2014-08-12 CN CN201410394695.6A patent/CN104116796B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1569187A (en) * | 2004-04-27 | 2005-01-26 | 秦学彬 | Pure Chinese medicine for treating infecundity, dysgenesia and mastopathia |
| CN101564521A (en) * | 2009-05-20 | 2009-10-28 | 石振刚 | External plaster for treating hyperplasia of mammary glands |
| CN102091296A (en) * | 2011-01-24 | 2011-06-15 | 郭智义 | Medicament for treating breast hyperplasia |
Non-Patent Citations (2)
| Title |
|---|
| 中医药治疗乳腺增生病概况;胡德祥;《河北中医》;20080428(第04期);第445-447页 * |
| 乳腺增生病辨治体会;李政;《江苏中医药》;20121231;第31-32页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104116796A (en) | 2014-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ried | Chinese herbal medicine for female infertility: an updated meta-analysis | |
| US11129863B2 (en) | Composition, preparation method thereof, and application thereof in the prevention and treatment of mammary gland disease | |
| CN104116796B (en) | A kind of pharmaceutical composition for the treatment of cyclomastopathy | |
| CN106334060B (en) | Pharmaceutical composition for treating obesity type polycystic ovarian syndrome | |
| CN102755600B (en) | Traditional Chinese medicine compound for resisting breast cancer metastasis and reoccurrence, preparation method and uses | |
| CN103479887B (en) | Traditional Chinese medicine formula for treating climacteric dysfunctional uterine bleeding | |
| CN103599367B (en) | Capsule for gastrointestinal ulcer and preparation technology thereof | |
| CN105943651A (en) | Traditional Chinese medicine composition for treating premature ovarian failure, and application thereof | |
| CN103585573B (en) | Oral medicine for treating hysteromyoma | |
| CN102784361B (en) | Traditional Chinese medicine composition for treating breast hyperplasia | |
| CN101693084B (en) | Medical composition for treating epigastric pain yin deficiency syndrome and preparation method thereof | |
| CN104491459A (en) | Traditional Chinese medicine composition for treating tumors | |
| CN104225016B (en) | A kind of pharmaceutical composition treating due to weakness of spleen and stomach chronic atrophic gastritis | |
| CN103479737A (en) | Traditional Chinese medicine composition for treating senile cutaneous pruritus and application thereof | |
| CN104013704B (en) | Pharmaceutical composition for treating chronic pelvic inflammatory disease and preparation method of composition | |
| CN105982906A (en) | Application of 20(R)-ginsenoside Rg3 in preparing medicines or health products capable of alleviating or/and treating rheumatoid diseases and medicines | |
| CN103860786A (en) | Medicine for treating puerperal fever | |
| CN103800736A (en) | Pharmaceutical composition for treating hypertensive nephrosclerosis and application of pharmaceutical composition | |
| CN103385953B (en) | A traditional Chinese medicine composition for the treatment of menopausal uterine fibroids and applications thereof | |
| CN105169106A (en) | Traditional Chinese medicinal preparation for treating hyperplasia of mammary glands | |
| CN105250952B (en) | A kind of Chinese medicine composition for treating uterus adenomyosis | |
| CN106266500B (en) | A kind of Chinese medicine composition for treating the proliferation of mammary gland | |
| CN105412280A (en) | Traditional Chinese medicine preparation for treating hepatic stones and gall-stones | |
| CN104491594A (en) | Pharmaceutical composition for treating premature ovarian failure | |
| CN104474513A (en) | Medicine for treating endometriosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160309 Termination date: 20160812 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |